Diamyd Medical AB

DMYD B

SE0005162880

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 11:29:36 2024-05-17 am EDT			5-day change	1st Jan Change
12.02 ^SEK	+0.50%		+10.48%	+82.95%

May. 16	Diamyd Medical AB Updates on the Registrational Phase 3 Trial	CI
Apr. 18	Diamyd Medical Raises SEK57 Million in Rights Issue	MT

Diamyd Medical AB Elects Karin Hehenberger as Board Member

December 02, 2021 at 10:45 am EST

Diamyd Medical AB (publ) at the AGM held on December 2, 2021, the shareholders M.D, Ph.D Karin Hehenberger, founder and CEO of Lyfebulb, was elected as a new Board member.

Latest news about Diamyd Medical AB

Diamyd Medical AB Updates on the Registrational Phase 3 Trial	May. 16	CI
Diamyd Medical Raises SEK57 Million in Rights Issue	Apr. 18	MT
Recruitment Milestone Reaches in Diamyd® Phase 3 Trial	Apr. 12	CI
Diamyd Medical AB Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	Mar. 27	CI
Diamyd Medical to Raise SEK114 Million Via Share Offering	Mar. 19	MT
Diamyd Medical to Present New Genetic Data at the ASIT Summit in Boston, MA	Feb. 29	CI
Diamyd Medical Secures US FDA Fast Track Designation for Type 1 Diabetes Treatment	Feb. 15	MT
In-Depth Analysis of Diamyd Medical AB's Phase II Trial Further Supports Value of Presented Insulin Production	Jan. 24	CI
Diamyd Medical AB Reports Earnings Results for the First Quarter Ended November 30, 2023	Jan. 24	CI
Diamyd Medical S.A. Announces Interim Analysis of the Transformational Gene-Based Precision Medicine Phase 3 Trial, DIAGNODE-3, for Type 1 Diabetes Is Planned for July 2024	Jan. 04	CI
Certain B Shares of Diamyd Medical AB are subject to a Lock-Up Agreement Ending on 27-DEC-2023.	Dec. 26	CI
Diamyd Medical's Precision Medicine Patent for the Prevention and Treatment of Autoimmune Diabetes Granted in South Korea	Dec. 06	CI
Diamyd Medical AB Elects Karin Rosén as A New Member of the Board	Nov. 30	CI
Diamyd Medical Partners With DiaUnion for Diabetes Drug Trial	Nov. 07	MT
Diamyd Medical Partners with Diamyd Medical to Recruit Participants for Type 1 Diabetes Prevention Trial	Nov. 07	CI
Diamyd Medical Raises SEK78 Million from Partially Subscribed Rights Issue	Nov. 02	MT
Diamyd Medical to Raise SEK78 Million from Partially Subscribed Rights Issue; Stock Jumps	Nov. 01	MT
Diamyd Medical Reports Updated Data on Subcutaneous Treatment to Delay Type 1 Diabetes Onset in Kids	23-10-26	MT
Diamyd Medical AB Announces Follow-Up Study Recommends Diamyd to Offer Advantages in Delivering Type 1 Diabetes Onset	23-10-26	CI
Transcript : Diamyd Medical AB - Special Call	23-10-20
Diamyd Medical’s Diabetes Drug Shows Booster Safety in Mid-stage Study; Shares Jump	23-10-20	MT
Diamyd Medical AB Announces Preliminary Results from Booster Trial with Diamyd Provide Additional Support for Intralymphatic Injection	23-10-20	CI
Diamyd Medical AB Reports Earnings Results for the Fourth Quarter Ended August 31, 2023	23-10-11	CI
Diamyd Medical AB Reports Earnings Results for the Full Year Ended August 31, 2023	23-10-11	CI
Diamyd Medical Founder Joins as Chairman	23-10-02	MT

Diamyd Medical AB is a Sweden-based diabetes company. It is active in the field of pharmaceutical development and investments in stem cell and medical technology. The Company develops the diabetes vaccine, Diamyd, with the active glutamic acid decarboxylase (GAD) ingredient for the treatment and prevention of autoimmune diabetes. The vaccine is intended for the treatment of children and adolescents with recent-onset type one diabetes, as well as those at high risk of developing the disease.

Sector

Biotechnology & Medical Research

Calendar

2024-06-25 - Q3 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Diamyd Medical AB

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
DIAMYD MEDICAL AB	+82.95%	115M
VERTEX PHARMACEUTICALS INCORPORATED	+8.98%	114B
REGENERON PHARMACEUTICALS, INC.	+11.36%	104B
BIONTECH SE	-12.43%	22.41B
ARGENX SE	-1.05%	22.28B
GENMAB A/S	-5.29%	19.07B
WUXI APPTEC CO., LTD.	-38.29%	18B
BEIGENE, LTD.	-2.46%	17.89B
NEUROCRINE BIOSCIENCES, INC.	+8.11%	14.28B
SAREPTA THERAPEUTICS, INC.	+34.93%	12.55B

Bio Therapeutic Drugs